Idera Pharmaceuticals (NASDAQ:IDRA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Earnings & Valuation
This table compares Idera Pharmaceuticals and Entera Bio’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Idera Pharmaceuticals||$660,000.00||107.55||-$59.88 million||($2.28)||-1.13|
Insider and Institutional Ownership
44.7% of Idera Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.0% of Entera Bio shares are owned by institutional investors. 20.5% of Idera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Idera Pharmaceuticals and Entera Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Idera Pharmaceuticals and Entera Bio, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Idera Pharmaceuticals currently has a consensus price target of $19.00, suggesting a potential upside of 639.30%. Entera Bio has a consensus price target of $12.00, suggesting a potential upside of 181.03%. Given Idera Pharmaceuticals’ higher possible upside, research analysts plainly believe Idera Pharmaceuticals is more favorable than Entera Bio.
Idera Pharmaceuticals beats Entera Bio on 6 of the 9 factors compared between the two stocks.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.
About Entera Bio
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.